Platelet-Rich Plasma in the Treatment of Musculoskeletal Disease in 2025 and Beyond
Steadman Clinic · Steadman Philippon Research Institute
Abstract
Platelet-rich plasma (PRP) is a blood-based orthobiologic used to treat a myriad of musculoskeletal conditions. While in vitro and preclinical studies on PRP have been promising, clinical results have been mixed. The heterogeneity in clinical benefits is attributable to both the complexity and variability of PRP as a biologic as well as the diversity of targeted tissues and ailments. Many variables have been proposed to affect PRP's bioactivity and clinical effects, with differing levels of evidence demonstrated for each variable. These variables can be broadly categorized as biological, technical, and abnormality-specific factors. Additionally, insufficient characterization of PRP in clinical studies has been…
Citation impact
- FWCI
- 89.65
- Percentile
- 99%
- References
- 146
Authors
10- BBBenjamin B. RothrauffCorresponding
Steadman Clinic, Steadman Philippon Research Institute
- JFJoseph Featherall
Steadman Clinic, Steadman Philippon Research Institute
- TJTyler J. Uppstrom
Steadman Clinic, Steadman Philippon Research Institute
- GGGreta Gohring
Steadman Philippon Research Institute
- ALAnna Laura Nelson
Steadman Philippon Research Institute
Topics & keywords
- Disease
- Clinical trial
- Musculoskeletal disease
- Musculoskeletal pain
- Clinical disease
- MEDLINE